Multinational Suitors Queue Up As India's Paras Pharma Valuation Shoots Above $1 Billion
This article was originally published in The Pink Sheet Daily
Among expected MNC bidders in the equity holding are GlaxoSmithKline, which is likely represented by Merrill Lynch; and Sanofi-Aventis, which is said to have mandated London-headquartered Rothschild to assist with its bid. Novartis and Johnson & Johnson are also considered to be potential buyers.
You may also be interested in...
The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.